Evidence map›Paper›PMID 30089476›Full record

ArticleBMC infectious diseases2018

Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar.

Mohammad H Al-Shaer, Hazem Elewa, Yosra Alkabab, Lama H Nazer, Scott K Heysell

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Mohammad H Al-ShaerInfectious Disease Pharmacokinetics Lab, College of Pharmacy, Emerging Pathogens Institute, University of Florida, Gainesville, FL, 32610, USA. mshaer@ufl.edu.ORCID 0000-0003-1432-5175
Hazem ElewaCollege of Pharmacy, Qatar University, Doha, Qatar.
Yosra AlkababDivision of Infectious Diseases, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.
Lama H NazerDepartment of Pharmacy, King Hussien Cancer Center, Amman, Jordan.
Scott K HeysellDivision of Infectious Diseases, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.
University of Virginia · USAmerican Association of Colleges of Pharmacy · USKing Hussein Cancer Center · JOQatar University · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes is associated with increased risk of tuberculosis (TB) treatment failure, death, and relapse compared to patients without diabetes. Current TB regimens are available as fixed dose combination (FDC) and separate tablets (ST), in which using the former is purported to make it easier to adhere and complete treatment. So far there are no studies assessing the performance of FDC compared to ST in diabetic patients with pulmonary TB. METHODOLOGY: A retrospective cohort study was conducted, and included eight hospitals in Qatar in which patients diagnosed with pulmonary TB received rifampin, isoniazid, pyrazinamide, and ethambutol (as FDC or ST) given as directly observed therapy. Sputum smears for acid fast bacilli were tested weekly. We included patients admitted between December 2012 and December 2015, ≥18 years old, diagnosed with TB with pretreatment positive sputum smears, and having diabetes. Patients with Mycobacterium tuberculosis that was resistant to any first-line drug were excluded. Blood glucose was monitored closely and controlled to < 180 md/dL using oral hypoglycemic agents and/or insulin. We assessed the effectiveness of TB regimens by comparing time to confirmed negative smears between those treated with FDC or ST, and the impact of adding metformin.

results103 patients met inclusion criteria. Mean age and body mass index were 45.6 ± 9.1 years and 22.1 ± 3.6 kg/m

conclusionPatients with diabetes and prescribed FDC showed faster smear conversion during treatment for pulmonary TB compared to ST which was more pronounced in those with 3+ bacillary load pretreatment and which appeared to be modified by higher dose metformin.

Indexed as

AdultAgedAntitubercular AgentsDiabetes ComplicationsDiabetes MellitusDose-Response Relationship, DrugFemaleHumansHypoglycemic AgentsMaleMiddle AgedMycobacterium tuberculosisQatarRetrospective StudiesSputumTabletsAntitubercular AgentsHypoglycemic AgentsTabletsDiabetesEffectivenessFixed-doseSeparate tabletsTuberculosis

Identifiers

PMID30089476
PMCPMC6083564
OpenAlexW2886104357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.